EP0971744A2 - COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS - Google Patents

COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Info

Publication number
EP0971744A2
EP0971744A2 EP98910075A EP98910075A EP0971744A2 EP 0971744 A2 EP0971744 A2 EP 0971744A2 EP 98910075 A EP98910075 A EP 98910075A EP 98910075 A EP98910075 A EP 98910075A EP 0971744 A2 EP0971744 A2 EP 0971744A2
Authority
EP
European Patent Office
Prior art keywords
iso
butyl
propyl
pentyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910075A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert E. Manning
Kevin C. Glenn
Bradley T. Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0971744(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of EP0971744A2 publication Critical patent/EP0971744A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to novel benzothiepines, derivatives and analogs thereof, in combination with HMG Co-A reductase inhibitors, pharmaceutical compositions containing them, and use of these compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as is associated with atherosclerosis or hypercholesterolemia, in mammals.
  • cholestyramine binds the bile acids in the intestinal tract, thereby interfering with their normal enterohepatic circulation (Reihner, E. et al, in "Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG- CoA reductase activity and low density lipoprotein receptor expression in gallstone patients", Journal of ioid Research. Volume 31, 1990, 2219-2226 and Suckling el al, "Cholesterol Lowering and bile acid excretion in the hamster with cholestyramine treatment", Atherosclerosis. 89(1991) 183-190).
  • the ileal bile acid transport system is a putative pharmaceutical target for the treatment of hypercholesterolemia based on an interruption of the enterohepatic circulation with specific transport inhibitors (Kramer, et al, "Intestinal Bile Acid Absorption” The Journal ' of Biolo g ical Chemistr y . Vol. 268, No. 24, Issue of August 25, pp. 18035-18046, 1993).
  • Hoechst Aktiengesellschaft discloses polymers of various naturally occurring constituents of the enterohepatic circulation system and their derivatives, including bile acid, which inhibit the physiological bile acid transport with the goal of reducing the LDL cholesterol level sufficiently to be effective as pharmaceuticals and", in particular for use as hypocholesterolemic agents .
  • Selected benzothiepines are disclosed in world patent application number W093/321146 for numerous uses including fatty acid metabolism and coronary vascular diseases .
  • benzothiepines are disclosed for use in various disease states not within the present invention utility. These are EP 568 898A as abstracted by Derwent Abstract No. 93-351589; WO 89/1477/A as abstracted in Derwent Abstract No. 89- 370688; U.S. 3,520,891 abstracted in Derwent 50701R-B; US 3,287,370, US 3,389,144; US 3,694,446 abstracted in Derwent Abstr. No. 65860T-B and WO 92/18462.
  • HMG Co-A reductase inhibitors have been used as cholesterol-lowering agents.
  • This class of compounds inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co- A) reductase.
  • HMG Co- A 3-hydroxy-3-methylglutaryl-coenzyme A
  • This enzyme catalyzes the conversion of HMG Co-A to mevalonate, which is an early and rate- limiting step in the biosynthesis of cholesterol .
  • Benzothiazepine anti-hyperlipidemic agents are disclosed in WO 94/18183, WO 94/18184, WO 96/05188, WO 96/16051, AU-A-30209/92, AU-A-61946/94 , AU-A-61948/94 , and AU-A- 61949/94.
  • the present invention furthers such efforts by providing novel pharmaceutical compositions and methods for the treatment of hyperlipidemic conditions.
  • R and R are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl) aryl, and cycloalkyl, wherein alkyl, alkenyl, alkynyl, haloalkyl, alkylaryl, arylalkyl, alkoxy, alkoxyalkyl, dialkylamino, alkylthio, (polyalkyl) aryl, and cycloalkyl optionally are substituted with one or more substituents selected from the group consisting of OR ,
  • R , R , and R w are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocycle, heteroaryl, ammoniumalkyl , alkylammoniumalkyl, and arylalkyl; or
  • R and R are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyloxy, aryl, , NR 9 R 10 , SR 9 , S(0)R 9 ,
  • R and R are independently selected from the group consisting of H, alkyl, alkenyl, alkenylalkyl , alkynylalkyl , heterocycle, ⁇ ca ⁇ >xyalkyl , carboalkoxyalkyl , ' cycloalkyl, cyanoalkyl, OR 9 , NR 9 R 10 , SR 9 , S(0)R 9 ,
  • R and R cannot be OH, NH and S ' or R 11 and R12 together with the nitrogen or carbon atom to which they are attached form a cyclic ring;
  • R and R are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl ⁇ heterocycle, ⁇ quaternary heterocycle, and quaternary heteroaryl can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, eteroaryl arylalkyl, quaternary heterocycle, quaternary heteroaryl, halogen, oxo, OR 13 , NR 13 R 14 , SR 13 , S(0)R 13 ,
  • a ⁇ is a pharmaceutically acceptable anion and M is a pharmaceutically acceptable cation
  • said alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, h eterocyc l e and h eteroaryl can be further substituted with one or more substituent groups selected from the group consisting of OR ,
  • alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, eterocycle and heteroaryl can optionally have one or more carbons replaced by 0,
  • R 13 , R 14 , and R 15 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, polyalkyl, aryl, arylalkyl, cycloalkyl, heterocycle, heteroaryl quaternary heterocycle, quaternary heteroaryl, and quaternary heteroarylalkyl, wherein alkyl, alkenyl, alkynyl, arylalkyl, heteroaryl, heterocycle, A and polyalkyl optionally have one or more carbons replaced by 0, NR J , N + R 9 R 10 A-, S, SO, S ⁇ 2 ,
  • R , R , and R are optionally substituted with one or more groups selected from the group consisting of sulfoa kyiTA quaternary heterocycle, quaternary heteroaryl, OR 9 , NR 9 R 10 , N + R 9 R 1:L R 12 A " , SR 9 , S(0)R 9 ,
  • R 16 and R17 are independently selected from the substituents constituting R and M; or R 14 and R15 , together with the nitrogen atom to which they are attached, form a cyclic ring;
  • R 7 and R8 are independently selected from the group consisting of hydrogen and alkyl; and one or more R x are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, polyalkyl, acyloxy, aryl, arylalkyl, halogen, haloalkyl, cycloalkyl, heterocycle, heteroaryl polyether, quaternary heterocycle, quaternary heteroaryl, OR 13 , NR 13 R 14 , SR 13 , S(0)R 13 , S(0)2R 13 ,
  • alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryli polyalkyl, heterocycle,y acyloxy, arylalkyl, haloalkyl, polyether, quaternary heterocycle, and quaternary heteroaryl can be further substituted with OR 9 , NR 9 R 10 , N + R 9 R 11 R 12 A " , SR 9 , S(0)R 9 , S0 2 R 9 , S03R 9 , oxo, C0 2 R 9 , CN, halogen, CONR 9 R 10 , SO2OM, S ⁇ 2NR 9 R 10 , P0(0R 1S )0R 17 , P + R 9 R 11 R 12 A ⁇ , S * R 5 R 10 A " , or C(0)OM, and wherein R 18 is selected from the group consisting of acyl, arylalkoxycarbonyl, arylalkyl, heterocycle, heteroaryl, alky
  • P P(0)R 13 p R R A- phenylene, amino acid, peptid.e, polypeptide, carbohydrate, polyether, or polyalkyl, wherein in said polyalkyl, phenylene, amino acid, peptide, polypeptide, and carbohydrate, one or more carbons are optionally replaced by 0, NR 9 , N+R9R10A-,
  • quaternary heterocycle and quaternary heteroaryl are optionally substituted with one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycT ⁇ afylalkyl , halogen, oxo, OR 13 , NR 13 R 14 , SR 13 , S(0)R 13 , S02R 13 , S03R 13 ,
  • NR 13 OR 14 NR 13 NR 14 R 15 , N02 , C02R 13 , CN, OM, S020M,
  • R 13 R 14 R 15 A _, P(OR")OR 14 , S * R 13 R 14 A ⁇ and N+RW , provided that both R and R cannot be hydrogen, OH, ojrr SSHH-,, aanndd wwhheenn RR 5 iis OH, R 1 , R 2 , R 3 , R 4 , R 7 and R 8 cannot be all hydrogen; provided that when R or R is phenyl, only one of R 1 or R 2 is H; provided that when q 1 and R x is styryl, anilido, or anilinocarbonyl, only one of R 5 or R ⁇ is alkyl ; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
  • R and R can independently be selected from the group consisting of H, aryl, heterocycle ⁇ quaternary heterocycle, and quaternary heteroaryl, wherein said aryl, heterocycle, heteroaryl, quaternary heterocycle, and quaternary heteroaryl can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl aryl, haloalkyl, cycloalkyl, heter cyS'e ⁇ arylalkyl, halogen, oxo, OR 13 , NR 13 R 14 , SR 13 , S(0)R 13 , S02R 13 , S03R 13 , NR 13 OR 14 , NR 13 NR 14 R 15 , N02 , C02R 13 , CN, OM, SO2OM,
  • R s or R ⁇ has the formula:
  • t is an integer from 0 to 5;
  • R 5 or R 6 has the formula (II) :
  • the invention is further directed to a compound selected from among:
  • R 1 ' is selected from the group consisting of alkane diyl, alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide, wherein alkane diyl, 'alkene diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide can optionally have one or more carbon atoms replaced by O, NR 7 , N + R 7 R 8 , S, SO, S0 2 , S + R R ,.
  • alkane diyl alken ⁇ diyl, alkyne diyl, polyalkane diyl, alkoxy diyl, polyether diyl, polyalkoxy diyl, carbohydrate, amino acid, peptide, and polypeptide can be substituted with one or more substituent groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, polyalkyl, polyether, aryl, haloalkyl, cycloalkyl, heterocycle, heteroaryl, arylalkyl, halogen, oxo, OR 13 , NR 13 R 14 , SR 13 , S(0)R 13 ,
  • R -,1* further comprises functional linkages by which R" is bonded to R a ⁇ R J1 , or R M in the compounds of Formulae DII and Dill, and R M in the compounds of Formula Dili.
  • R , ⁇ , R", or R M and R M comprises a benzothiepine moiety as described above that is therapeutically ' effective in inhibiting ileal bile acid transpor .
  • the invention is also directed to a compound selected from among Formula DI, Formula DII and Formula Dili in which each of R al , R M and " comprises a benzothiepine moiety corresponding to the Formula:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R ⁇ , R 7 , R ⁇ R x , q, and n are as defined in Formula I as described above, and R 55 is either a covalent bond or arylene.
  • each of R 20 , R 21 , and R 22 in Formulae DII and Dili, and R 23 in Formula Dili be bonded at its 7- or 8-position to R 1 '.
  • R 5S comprise a phenylene moiety bonded at a m- or p-carbon thereof to R 19 .
  • Formula DI examples include:
  • benzothiepine compounds of the present invention can be used' alone or in various combinations .
  • R 1 and R 2 can be ethyl/butyl or butyl/butyl.
  • the present invention provides a pharmaceutical composition for the prophylaxis or treatment of a disease or condition for which a bile acid transport inhibitor is indicated, such as a hyperlipidemic condition, for example, atherosclerosis.
  • a pharmaceutical composition for the prophylaxis or treatment of a disease or condition for which a bile acid transport inhibitor is indicated such as a hyperlipidemic condition, for example, atherosclerosis.
  • Such compositions comprise any of the compounds disclosed above, alone or in combination, in an amount effective to reduce bile acid levels in the blood, or to reduce transport thereof across digestive system membranes, and a pharmaceutically acceptable carrier, excipient, or diluent.
  • the present invention also provides a method of treating a disease or condition in mammals, including humans, for which a bile acid transport inhibitor is indicated, comprising administering to a patient in need thereof a compound of the present invention in an effective amount in unit dosage form or in divided doses .
  • the present invention also provides processes for the preparation of compounds of the present invention.
  • the present invention provides a combination therapy comprising the use of a first amount of an ileal bile acid transport inhibitor and a second amount of a HMG Co-A reductase inhibitor useful to treat hyperlipidemic disorders, wherein said first and second amounts together comprise an anti- hyperlipidemic condition effective amount of said compounds .
  • HMG Co-A reductase inhibitor- compounds useful in the present invention are shown in Appendix B.- Further scope of the applicability of the present invention will become apparent from the detailed description provided below. However, it should be
  • Alkyl alkenyl
  • alkynyl unless otherwise noted are each straight chain or branched chain hydrocarbons of from one to twenty carbons for alkyl or two to twenty carbons for alkenyl and alkynyl in the present invention and therefore mean, for example, methyl, ethyl, propyl, butyl, pentyl or hexyl .and ethenyl, propenyl, butenyl, pentenyl, or hexenyl and ethynyl, propynyl, butynyl, pentynyl, or hexyriyl respectively and isomers thereof.
  • Aryl means a fully unsaturated mono- or multi- ring carbocyle, including, but not limited to, substituted or unsubstituted phenyl, naphthyl, or anthracenyl .
  • Heterocycle means a saturated or unsaturated mono- or multi-ring carbocycle wherein one or more carbon atoms can be replaced by N, S, P, or 0. This includes, for example, the following structures:
  • Z, Z', Z" or Z"' is C, S, P, 0, or N, with the proviso that one of Z, Z', Z" or Z" ' is other than carbon, but is not 0 or S when attached to another Z atom by a double bond or when attached to another 0 or S atom.
  • the optional substituents are understood to be attached to Z, Z', Z" or Z"' only when each is C.
  • heteroaryl means a fully unsaturated heterocycle. In either “heterocycle” or “heteroaryl,” the point of attachment to the molecule of interest can be at the heteroatom or elsewhere within the ring.
  • quaternary heterocycle means a heterocycle in which one or more of the heteroatoms, for example, 0, N, S, or P, has such a number of bonds that it is positively charged.
  • the point of attachment of the quaternary heterocycle to the molecule of interest can be at a heteroatom or elsewhere.
  • quaternary heteroaryl means a • heteroaryl in which one or more of the heteroatoms, for example, 0, N, S, or P, has such a number of bonds that it is positively charged.
  • the point of attachment of the quaternary heteryaryl to the molecule of interest can be at a heteroatom or elsewhere.
  • halogen means a fluoro, chloro, bromo or iodo group.
  • haloalkyl means alkyl substituted with one or more halogens .
  • cycloalkyl means a mono- or multi- ringed carbocycle wherein each ring contains three to ten carbon atoms, and wherein any ring can contain one or more double or triple bonds .
  • diyl means a diradical moiety wherein said moiety has two points of attachment to molecules of -interest.
  • oxo means a doubly bonded oxygen.
  • polyalkyl means a branched or straight hydrocarbon chain having a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5,000.
  • polyether means a polyalkyl wherein one or more carbons are replaced by oxygen, wherein the polyether has a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5, 000.
  • polyalkoxy means a polymer of alkylene oxides, wherein the polyalkoxy has a molecular weight up to about 20,000, more preferably up to about 10,000, most preferably up to about 5,000.
  • cycloaklylidene means a mono- or multi- ringed carbocycle wherein a carbon within the ring structure is doubly bonded to an atom which is not within the ring structures.
  • carbohydrate means a mono-, di-, tri-, or polysaccharide wherein the polysaccharide can have a molecular weight of up to about 20,000, for example, hydroxypropyl-methylcellulose or chitosan.
  • peptide means polyamino acid ' containing up to about 100 amino acid units.
  • polypeptide means polyamino acid containing from about 100 amino acid units to about
  • alkylammoniumalkyl means a NH. group or a mono-, di- or tri-substituted amino group, any of which is bonded to an alkyl wherein said alkyl is bonded to the molecule of interest.
  • triazolyl includes all positional isomers. In all other heterocycles and heteroaryls which contain more than one ring heteroatom and for which isomers are possible, such isomers are included in the definition of said heterocycles and heteroaryls.
  • sulfoalkyl means an alkyl group to which a sulfonate group is bonded, wherein said alkyl is bonded to the molecule of interest.
  • active compound means a compound of the present invention which inhibits transport of bile acids .
  • alkylaryl or “arylalkyl,” the individual terms listed above have the meaning indicated above.
  • a bile acid transport inhibitor means a compound capable of inhibiting absorption of bile acids from the intestine into the circulatory system of a mammal, such as a human. This includes increasing the fecal excretion of bile acids, as well as reducing the blood plasma or serum concentrations of cholesterol and cholesterol ester, and more specifically, reducing LDL and VLDL cholesterol.
  • Conditions or diseases which benefit from the prophylaxis or treatment by bile acid transport ' inhibition include, for example, a hyperlipidemic condition such as atherosclerosis.
  • combination therapy refers to the administration of an ileal bile acid transport inhibitor and a HMG Co-A reductase inhibitor to treat a hyperlipidemic condition, for example atherosclerosis and hypercholesterolemia.
  • Such administration encompasses co-administration of these inhibitors in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each inhibitor agent.
  • such administration also encompasses use of each type of inhibitor in a sequential manner.
  • the treatment regimen will provide beneficial effects of the drug combination in treating the hyperlipidemic condition.
  • the phrase "theraputically effective" is intended to qualify the combined amount of inhibitors in the combination therapy. This combined amount will achieve the goal of reducing or eliminating the hyperlipidemic condition.
  • the compounds of the present invention can have at least two asymmetrical carbon atoms, and therefore include racemates and stereoisomers, such as diastereomers and enantiomers, in both pure form and in admixture.
  • stereoisomers can be prepared using conventional techniques, either by reacting enantiomeric starting materials, or by separating isomers of compounds of the present invention.
  • Isomers may include geometric isomers, for example cis isomers or trans isomers across a double bond. All such isomers are contemplated among the compounds of the present invention.
  • the compounds of the present invention also include tautomers.
  • the compounds of the present invention as discussed below include their salts, solvates and prodrugs .
  • the compounds of the present invention can be prepared by the procedures described below.
  • reaction of aldehyde II with formaldehyde and sodium hydroxide yields the hydroxyaldehyde III which is converted to mesylate IV with methanesulfonyl chloride and triethylamine similar to the procedure described in Chem. Ber. 98, 728-734 (1965).
  • keto-aldehyde VI which can be cyclized with the reagent, prepared from zinc and titanium trichloride in refluxing ethylene glycol dimethyl ether (DME) , to give a mixture of 2 , 3-dihydrobenzothiepine VII and two racemic steroisomers of benzothiepin- (5Jf) -4-one VIII when R 1 and R 2 are nonequivalent .
  • Optically active compounds of the present invention can be prepared by. using optically active starting material III or by resolution of compounds X with optical resolution agents well known in the art as described in J". Org. Chem. , 39, 3904 (1974), ii>id. , 42, 2781 (1977), and ijbid., 44, 4891 (1979).
  • keto-aldehyde VI where R 2 is H can be prepared by reaction of thiophenol V with a 2- substituted acrolein.
  • Benzothiepin- (5H) -4-one VIII can be oxidized with MCPBA to give the benzothiepin- (5H) -4-one-l, 1-dioxide XII which can be reduced with sodium borohydride to give four racemic stereoisomers of X.
  • the two stereoisomers of X, Xa and Xb, having the OH group and R s on the opposite sides of the benzothiepine ring can be converted to the other two isomers of X, Xc and Xd, having the OH group and R 5 on the same side of the benzothiepine ring by reaction in methylene chloride with 40-50% sodium hydroxide in the presence of a phase transfer catalyst (PTC) .
  • PTC phase transfer catalyst
  • the transformation can also be carried out with potassium t-butoxide in THF.
  • R 5 is OR, NRR' or S(0) n R and R * is hydroxy
  • R 5 is OR, NRR' or S(0) n R and R * is hydroxy
  • R 5 OR, NRR 1 , S(0)R
  • the thiophenols XVIII and V used in the present invention can also be prepared according to the Scheme 3. Alkylation of phenol XV with an arylmethyl chloride in a nonpolar solvent according to the procedure in J". Chem. Soc , 2431-2432 (1958) gives the ortho substituted phenol XVI. The phenol XVI can be converted to the thiophenol XVIII via the thiocarbamate XVII by the procedure described in J. Org. Chem. , 31, 3980 (1966) .
  • phenol XVI is first reacted with dimethyl thiocarbamoyl chloride and triethylamine to give thiocarbamate XVII which is thermally rearranged at 200-300 °C, and the rearranged product is hydrolyzed with sodium hydroxide to yield the thiophenol XVIII.
  • Thiophenol V can also be prepared from 2- acylphenol XIX via the intermediate thiocarbamate XX.
  • Scheme 4 shows another route to benzothiepine-1, 1- dioxides Xc and Xd starting from the thiophenol XVIII.
  • Compound XVIII can be reacted with mesylate IV to give the sulfide-aldehyde XXI.
  • Oxidation of XXI with two equivalents of MCPBA yields the sulfone-aldehyde XIV which can be cyclized with potassium t-butoxide to a mixture of Xc and Xd.
  • Cyclyzation of sulfide-aldehyde with potassium t-butoxide also gives a mixture of benzothiepine XXIIc and XXIId.
  • Examples of amine- and hydroxylamine-containing compounds of the present invention can be prepared as shown in Scheme 5 and Scheme 6.
  • 2-Chloro-5- nitrobenzophenone is reduced with triethylsilane and trifluoromethane sulfonic acid to 2-chloro-5- nitrodiphenylmethane 32.
  • Reaction of 32 with lithium sulfide followed by reacting the resulting sulfide with mesylate IV gives sulfide-aldehyde XXIII.
  • Oxidation of XXIII with 2 equivalents of MCPBA yields sulfone- aldehyde XXIV which can be reduced by hydrogenation to the hydroxylamine XXV.
  • Protecting the hydroxylamine XXV with di-t-butyldicarbonate gives the N, 0-di-(t-
  • Scheme 7 describes one of the methods of introducing a substituent to the aryl ring at the 5- position of benzothiepine.
  • Iodination of 5-phenyl derivative XXX with iodine catalyzed by mercuric triflate gives the iodo derivative XXXI, which upon palladium-catalyzed carbonylation in an alcohol yields the carboxylate XXXII.
  • R 1 and R s can be selected from among substituted and unsubstituted C x to C 10 alkyl wherein the substituent (s) can be selected from among alkylcarbonyl, alkoxy, hydroxy, and nitrogen-containing heterocycles joined to the C L to C 10 alkyl through an ether linkage.
  • Ethyl, n-propyl, n-butyl, and isobutyl are preferred.
  • substituents R l and R J are identical, for example n-butyl/n-butyl, so that the compound is achiral at the 3-carbon. Eliminating optical isomerism at the 3-carbon simplifies the selection, synthesis, separation, and quality control of the compound used as an ileal bile acid transport inhibitor.
  • substituents (R * ) on the benzo- ring can include hydrogen, aryl, alkyl, hydroxy, halo, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkyl, haloalkoxy, (N) -hydroxy- carbonylalkyl amine, haloalkylthip, haloalkylsulfinyl, haloalkylsufonyl, amino, N-alkylamino, N,N- dialkylamino, (N) -alkoxycarbamoyl, (N) - aryloxycarbamoyl , (N) -aralkyloxycarbamoyl, trialkyl- ammonium (especially with a halide counterion) , (N) - amido, (N) -alkyl, hydroxy, halo, alkoxy, alkylthio, al
  • the benzo ring can be mono-substituted at the 6, 7 or 8 position, or disubstituted at the 7- and -8 positions. Also included are the 6, 7, 8-trialkoxy compounds, for example the 6, 7, 8-trimethoxy compounds.
  • substituents can be advantageously present on the 6, 7, 8, and/or 9- positions of the benzo ring, including, for example, guanidinyl, cycloalkyl, carbohydrate (e.g., a 5 or 6 carbon monosaccharide) , peptide, and quaternary ammonium salts linked to the ring via poly (oxyalkylene) linkages, e.g., - (OCH 2 CH 2 ) X -N * R"R"R 15 A " , where x is 2 to 10.
  • Exemplary compounds are those set forth below in Table 1.
  • 2-thiophene indicates a bond in the 2 position of the thiophene ring.
  • a similar convention is used for other heterocyclic substituents.
  • PEG 3400 molecular weight polyethylene glycol polymer chain
  • PEG 3400 molecular weight polyethylene glycol polymer chain
  • PEG 3400 molecular weight polyethylene glycol polymer chain
  • R 5 and R* are independently selected from among hydrogen and ring-carbon substituted or unsubstituted aryl, thiophene, pyridine, pyrrole, thiazole, imidazole, pyrazole, pyrimidine, morpholine, N-alkylpyridinium, N- alkyl-piperaziniu , N-alkylmorpholinium, or furan in which the substituent (s) are selected from among halo, hydroxyl, trihaloalkyl, alkoxy, amino, N-alkylamino, N,N-dialkylamino, quaternary ammonium salts, a C x to C t alkylene bridge having a quaternary ammonium salt substituted thereon, alkoxycarbonyl , aryloxycarbonyl , alkylcarbonyloxy and arylcarbonyloxy, (0,0)- dioxyalkylene, -[0(CH 2 )
  • the aryl group of R ! or R ⁇ is preferably phenyl, phenylene, or benzene triyl, i.e., may be unsubstituted, mono-substituted, or di- substituted.
  • the species which may constitute the substituents on the aryl ring of R 5 or R s are fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, trimethylammonium (preferably with an iodide or chloride counterion) , methoxycarbonyl, ethoxycarbonyl, for yl, acetyl, propanoyl, (N) -hexyldimethylammonium, hexylenetrimethylammonium, tri (oxyethylene) iodide, and tetra(oxyethylene) trimethylammonium iodide, each substituted at the p-position, the m-position, or both of the aryl ring.
  • R ! or R 6 is selected from phenyl, p-fluorophenyl, m-fluorophenyl, p- hydroxyphenyl , m-hydroxyphenyl , p-methoxyphenyl, - methoxyphenyl, p-N,N-dimethylaminophenyl, m-N,N-
  • IH2 dimethylaminophenyl I " p- (CH,),-N * -phenyl, I " m- (CH,),-N “ - phenyl. I " m- (CH,),-N * -CK-CH I -(OCH-CH.).-0-phenyl, I " p- (CH-) .-N “ -CH.CH-- (OCH.CH,) a -0-phenyl, I " ra- (N,N-dimethyl- piperazinium) - (N' ) -CH.- (0CH j CH,) 3 -0-phenyl, 3-methoxy-4- fluorophenyl, thienyl-2-yl, S-cholorothienyl-2-yl, 3, 4-difluorophenyl, I * p- (N,N-dimethylpiperaziniuai)- (N- )-CH a -(0CH J CH a
  • Preferred compounds include 3- ethyl-3-butyl and 3-butyl-3-butyl compounds having each of the above preferred R' substituents in combination with the R m substituents shown in Table 1. It is particularly preferred that one but not both of ' and R * is hydrogen.
  • R' and R* be hydrogen, that R 1 and R' not be hydrogen, and that R 1 and ' be oriented in the same direction relative to the plane of the molecule, i.e., both in ex- or both in ⁇ -configuration. It is further preferred that, where R* is butyl and R l is ethyl, then R 1 has the same orientation relative to the plane of the molecule as R 1 and R'.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98910075A 1997-03-11 1998-03-10 COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS Withdrawn EP0971744A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
US40660P 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
EP0971744A2 true EP0971744A2 (en) 2000-01-19

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910075A Withdrawn EP0971744A2 (en) 1997-03-11 1998-03-10 COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Country Status (16)

Country Link
EP (1) EP0971744A2 (https=)
JP (1) JP2002500628A (https=)
CN (1) CN1255864A (https=)
AU (1) AU730024C (https=)
BG (1) BG103793A (https=)
BR (1) BR9808013A (https=)
CA (1) CA2283575A1 (https=)
HU (1) HUP0002395A3 (https=)
IL (1) IL131872A0 (https=)
MX (1) MXPA99008417A (https=)
NO (1) NO994390L (https=)
NZ (1) NZ337830A (https=)
PL (1) PL336415A1 (https=)
RU (1) RU2247579C2 (https=)
SK (1) SK125099A3 (https=)
WO (1) WO1998040375A2 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
AU2003257578B2 (en) * 2002-08-28 2009-01-22 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN102293773A (zh) 2004-02-27 2011-12-28 旭化成制药株式会社 含有苯并硫氮杂卓和苯并虑平化合物的药物
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
JP6097695B2 (ja) 2010-11-08 2017-03-15 アルビレオ アクチエボラグ Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
WO2016045642A1 (en) 2014-09-28 2016-03-31 National Institute Of Biological Sciences, Beijing Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
ES2955799T3 (es) 2019-02-06 2023-12-07 Albireo Ab Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
PL3923943T3 (pl) 2019-02-12 2024-12-09 Mirum Pharmaceuticals, Inc. Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
CN112274648B (zh) * 2020-11-23 2022-10-14 郑州大学 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
TW202423921A (zh) * 2022-08-22 2024-06-16 美商安塔製藥公司 稠合的雜雙環抗病毒劑
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
ES2087422T3 (es) * 1991-12-20 1996-07-16 Hoechst Ag Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9840375A2 *

Also Published As

Publication number Publication date
JP2002500628A (ja) 2002-01-08
AU6440898A (en) 1998-09-29
MXPA99008417A (es) 2005-02-03
CN1255864A (zh) 2000-06-07
AU730024B2 (en) 2001-02-22
SK125099A3 (en) 2001-02-12
BG103793A (en) 2000-07-31
HUP0002395A2 (hu) 2001-05-28
CA2283575A1 (en) 1998-09-17
NZ337830A (en) 2001-07-27
IL131872A0 (en) 2001-03-19
BR9808013A (pt) 2001-09-25
AU730024C (en) 2004-08-05
NO994390D0 (no) 1999-09-10
NO994390L (no) 1999-11-04
PL336415A1 (en) 2000-06-19
HUP0002395A3 (en) 2002-12-28
WO1998040375A3 (en) 1998-12-03
WO1998040375A2 (en) 1998-09-17
RU2247579C2 (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
AU730024C (en) Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
EP0888333B1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6784201B2 (en) Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1997033882A9 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP1091953B1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU723123B2 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
AU761249B2 (en) Novel intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CZ322899A3 (cs) Kombinovaná terapie využívající ileální transport žlučových kyselin inhibovaný benzothiepiny HMG Co-A reduktázovými inhibitory
EP1440972A1 (en) Novel benzothiepines having pharmaceutical activity.
HK1068342A (en) Novel benzothiepines having pharmaceutical activity
HK1028735A (en) Combination therapy employing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990924

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: G.D. SEARLE LLC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003